PA
VIR icon

Profund Advisors’s Vir Biotechnology VIR Stock Holding History

Profund Advisors’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$745K Buy
73,077
+9,211
+14% +$87.6K 0.02% 421
2026
Q1 		$572K Buy
63,866
+7,173
+13% +$57.2K 0.02% 506
2025
Q4 		$342K Buy
56,693
+29,033
+105% +$173K 0.01% 784
2025
Q3 		$158K Sell
27,660
-2,516
-8% -$12.9K 0.01% 1012
2025
Q2 		$152K Sell
30,176
-7,749
-20% -$41.5K 0.01% 941
2025
Q1 		$246K Buy
37,925
+10,415
+38% +$92.6K 0.01% 794
2024
Q4 		$202K Sell
27,510
-9,954
-27% -$78.5K 0.01% 1010
2024
Q3 		$281K Buy
37,464
+7,336
+24% +$63.7K 0.01% 842
2024
Q2 		$268K Sell
30,128
-40,998
-58% -$393K 0.01% 787
2024
Q1 		$721K Buy
71,126
+2,343
+3% +$23.9K 0.03% 452
2023
Q4 		$692K Sell
68,783
-22,255
-24% -$203K 0.03% 417
2023
Q3 		$853K Buy
91,038
+31,029
+52% +$443K 0.05% 319
2023
Q2 		$1.47M Buy
60,009
+910
+2% +$22.9K 0.08% 214
2023
Q1 		$1.38M Buy
59,099
+45,932
+349% +$1.17M 0.09% 203
2022
Q4 		$333K Sell
13,167
-245
-2% -$6K 0.02% 583
2022
Q3 		$259K Sell
13,412
-83
-0.6% -$2.11K 0.02% 661
2022
Q2 		$344K Buy
13,495
+2,584
+24% +$60.3K 0.02% 559
2022
Q1 		$281K Sell
10,911
-1,196
-10% -$35.5K 0.01% 992
2021
Q4 		$507K Sell
12,107
-1,513
-11% -$59.3K 0.02% 604
2021
Q3 		$593K Buy
13,620
+537
+4% +$23.2K 0.02% 549
2021
Q2 		$619K Sell
13,083
-43
-0.3% -$1.96K 0.02% 548
2021
Q1 		$673K Sell
13,126
-1,253
-9% -$67.5K 0.03% 442
2020
Q4 		$385K Buy
14,379
+1,377
+11% +$44.8K 0.02% 675
2020
Q3 		$446K Buy
+13,002
New +$560K 0.02% 490

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Profund Advisors's VIR Position: Q2 2026 in Review

Profund Advisors increased its Vir Biotechnology (VIR) stake by 14% in Q2 2026, buying an estimated $87.6K and bringing the position to 73,077 shares worth $745K. The position accounts for 0.02% of the portfolio, ranked #421.

Profund Advisors first reported a position in VIR in Q3 2020 and has held it in 24 quarters since. The position peaked at $1.47M in Q2 2023. 238 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • Profund Advisors held 73,077 shares of Vir Biotechnology worth $745K as of Q2 2026.
  • Profund Advisors bought 9,211 Vir Biotechnology shares in Q2 2026, an estimated $87.6K.
  • Vir Biotechnology made up 0.02% of Profund Advisors's portfolio in Q2 2026, its #421 holding.
  • Profund Advisors first reported a position in Vir Biotechnology in Q3 2020 and has held it in 24 quarters since.
  • Profund Advisors's Vir Biotechnology position peaked at $1.47M in Q2 2023.
  • 238 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.